Proposed Medicaid Drug Pricing Rule Has Implications for 340B

by Admin | February 17, 2012 12:35 pm

February 17, 2012—The Centers for Medicare and Medicaid Services’ (CMS) long-awaited proposed rule[1] to implement health care reform’s changes to the Medicaid drug rebate program would continue policies put in place late last year that have likely resulted in higher 340B prices for most covered outpatient drugs but lower 340B prices for the smaller class of so-called “5i” inhalation, infusion, instilled, implanted or injectable medications.

It is unclear, though, how drug manufacturers will respond to language in the proposal regarding 340B discounts on orphan drugs to rural and free-standing cancer hospitals that became eligible for 340B under the Affordable Care Act (ACA) in 2010. 

---

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[2].    Already registered? Click here to login[3]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Source URL: https://340binformed.org/2012/02/proposed-medicaid-drug-pricing-rule-has-implications-for-340b/

---